The Mechanism of Action of CDK4/6 Inhibitors

Conference Correspondent  - SABCS 2017 - Breast Cancer, Breast Cancer, Video
Matthew P. Goetz, MD
Dr Matthew Goetz explains the rationale for using CDK4/6 inhibitors in patients with HR-positive metastatic breast cancer.
Related Items
Working Together to Find the New Standard of Care
Andrey Antov, PhD, MBA
Video Library published on September 6, 2018 in Video
Opportunities Are Abundant for Navigators in the Field of Genetics and Genomics
Andrey Antov, PhD, MBA
Video Library published on September 6, 2018 in Video
Healthcare Team's Relationship to the Patient
Andrey Antov, PhD, MBA
Video Library published on September 6, 2018 in Video
The Navigator's Role in Genetic Testing
Andrey Antov, PhD, MBA
Video Library published on September 6, 2018 in Video
Why Are Clinical Trials Important?
Andrey Antov, PhD, MBA
Video Library published on September 6, 2018 in Video
Educating Oncology Professionals on Genetic and Genomic Testing
Andrey Antov, PhD, MBA
Video Library published on September 6, 2018 in Video
Who Should Consider Genetic Testing?
Andrey Antov, PhD, MBA
Video Library published on September 6, 2018 in Video
Acquired HER2 Mutations in Metastatic Breast Cancer Confer Resistance to ER-Directed Therapy
Phoebe Starr
TOP - August 2018, Vol 11, No 2 published on August 3, 2018 in Breast Cancer
What the Next Generation of Cancer Biomarkers May Involve
Sanjiv Agarwala, MD
Video Library published on July 25, 2018 in 2018 ASCO Insights, Video
How MSI and TMB Factor into Current Biomarker Testing Panels
Sanjiv Agarwala, MD
Video Library published on July 25, 2018 in 2018 ASCO Insights, Video
Last modified: January 10, 2018